Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Karuna Therapeutics Inc
(NQ:
KRTX
)
329.83
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Analyst Ratings for Karuna Therapeutics
June 28, 2022
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:
Via
Benzinga
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
May 26, 2022
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT...
Via
Benzinga
Analyst Ratings for Karuna Therapeutics
May 24, 2022
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Karuna Therapeutics: Q1 Earnings Insights
May 05, 2022
Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Karuna Therapeutics
April 27, 2022
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
February 24, 2022
According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
March 31, 2022
Upgrades
Via
Benzinga
This Metaverse Stock Will Be Featured On 'Mad Money' Wednesday Night
December 01, 2021
Unity Software Inc (NYSE:U) CEO John Riccitiello
Via
Benzinga
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
November 13, 2021
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
Via
Talk Markets
Why Karuna Therapeutics Stock Tumbled This Week
November 12, 2021
Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.
Via
The Motley Fool
76 Biggest Movers From Yesterday
November 11, 2021
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates
November 09, 2021
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
Biotechs Ready To Roar
June 13, 2021
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...
Via
Talk Markets
Exposures
Product Safety
10 Biggest Price Target Changes For Monday
April 26, 2021
Credit Suisse boosted Facebook, Inc. (NASDAQ: FB) price target from $330 to $371. Facebook shares rose 0.4% to $302.18 in pre-market trading. Citigroup raised the price target...
Via
Benzinga
Cramer Gives His Opinion On Regeneron, Bumble And More
April 14, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said NIH and CDC should get their act together and start pushing what Regeneron Pharmaceuticals Inc (NASDAQ: REGN)...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.